Cargando…
176例再生障碍性贫血患者门诊治疗真实世界研究
OBJECTIVE: To explore the diagnostic process and outcomes of patients with aplastic anemia (AA) who received outpatient treatment in a real-world setting. METHODS: The diagnostic processes, treatment regimens, and outcomes of 176 patients with AA treated in outpatient centers from January 2018 to De...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957255/ https://www.ncbi.nlm.nih.gov/pubmed/33677870 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.01.011 |
_version_ | 1783664616695398400 |
---|---|
collection | PubMed |
description | OBJECTIVE: To explore the diagnostic process and outcomes of patients with aplastic anemia (AA) who received outpatient treatment in a real-world setting. METHODS: The diagnostic processes, treatment regimens, and outcomes of 176 patients with AA treated in outpatient centers from January 2018 to December 2019 were reviewed. RESULTS: The median interval from the onset of symptoms to the first visit was 7 (5–120) months. Complaints during the first visit included bleeding (52.3%), anemia (51.7%), and infection (6.8%). For diagnosis, 168 patients (95.5%) underwent bone marrow aspiration; however, only 22 of them (17.1%) consented aspiration in multiple sites (sternum). The completion rate of bone marrow biopsy was 85.1% (143/168) ; flow immunophenotype and karyotype analyses were performed on 59.5% (100/168) and 58.9% (99/168) of AA patients, respectively, and the culture of clonal forming units by bone marrow mononuclear cells was performed on 26.8% (45/168) of AA patients. The most preferred regimen was cyclosporine combined with androgen and levamisole (43.8%, 77 patients), followed by cyclosporine combined with androgen (25.6%, 45 patients). Cyclosporine alone was administered in 24 patients (13.6%) and androgen alone in 16 patients (9.1%). Furthermore, 14 patients (7.9%) did not consent to any drugs or only chose traditional Chinese medicine. The patients were divided according to the frequencies of follow-up: regular follow-up group (≥4 times/year, n=130) and irregular group (<4 times/year, n=46). The former had a higher 6-month remission rate (52.5% vs 28.0%, P=0.005), a greater high-quality remission rate in 12 months (40.7% vs 16.7%, P=0.027), and a lower relapse rate in 24 months (4.4% vs 36.4%, P=0.001). CONCLUSION: In real-world settings, bone marrow aspiration in multiple sites should be addressed in outpatient treatment for AA diagnostic work-up, including PNH clone screening, flow immunophenotype, chromosome karyotype analysis, and culture of clonal forming units. Patients with AA who follow regular visits were more likely to achieve high-quality remission and a lower relapse rate. Visits at least four times per year are recommended for AA patients undergoing outpatient treatment. |
format | Online Article Text |
id | pubmed-7957255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-79572552021-03-15 176例再生障碍性贫血患者门诊治疗真实世界研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To explore the diagnostic process and outcomes of patients with aplastic anemia (AA) who received outpatient treatment in a real-world setting. METHODS: The diagnostic processes, treatment regimens, and outcomes of 176 patients with AA treated in outpatient centers from January 2018 to December 2019 were reviewed. RESULTS: The median interval from the onset of symptoms to the first visit was 7 (5–120) months. Complaints during the first visit included bleeding (52.3%), anemia (51.7%), and infection (6.8%). For diagnosis, 168 patients (95.5%) underwent bone marrow aspiration; however, only 22 of them (17.1%) consented aspiration in multiple sites (sternum). The completion rate of bone marrow biopsy was 85.1% (143/168) ; flow immunophenotype and karyotype analyses were performed on 59.5% (100/168) and 58.9% (99/168) of AA patients, respectively, and the culture of clonal forming units by bone marrow mononuclear cells was performed on 26.8% (45/168) of AA patients. The most preferred regimen was cyclosporine combined with androgen and levamisole (43.8%, 77 patients), followed by cyclosporine combined with androgen (25.6%, 45 patients). Cyclosporine alone was administered in 24 patients (13.6%) and androgen alone in 16 patients (9.1%). Furthermore, 14 patients (7.9%) did not consent to any drugs or only chose traditional Chinese medicine. The patients were divided according to the frequencies of follow-up: regular follow-up group (≥4 times/year, n=130) and irregular group (<4 times/year, n=46). The former had a higher 6-month remission rate (52.5% vs 28.0%, P=0.005), a greater high-quality remission rate in 12 months (40.7% vs 16.7%, P=0.027), and a lower relapse rate in 24 months (4.4% vs 36.4%, P=0.001). CONCLUSION: In real-world settings, bone marrow aspiration in multiple sites should be addressed in outpatient treatment for AA diagnostic work-up, including PNH clone screening, flow immunophenotype, chromosome karyotype analysis, and culture of clonal forming units. Patients with AA who follow regular visits were more likely to achieve high-quality remission and a lower relapse rate. Visits at least four times per year are recommended for AA patients undergoing outpatient treatment. Editorial office of Chinese Journal of Hematology 2021-01 /pmc/articles/PMC7957255/ /pubmed/33677870 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.01.011 Text en 2021年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 论著 176例再生障碍性贫血患者门诊治疗真实世界研究 |
title | 176例再生障碍性贫血患者门诊治疗真实世界研究 |
title_full | 176例再生障碍性贫血患者门诊治疗真实世界研究 |
title_fullStr | 176例再生障碍性贫血患者门诊治疗真实世界研究 |
title_full_unstemmed | 176例再生障碍性贫血患者门诊治疗真实世界研究 |
title_short | 176例再生障碍性贫血患者门诊治疗真实世界研究 |
title_sort | 176例再生障碍性贫血患者门诊治疗真实世界研究 |
topic | 论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957255/ https://www.ncbi.nlm.nih.gov/pubmed/33677870 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.01.011 |
work_keys_str_mv | AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū AT 176lìzàishēngzhàngàixìngpínxuèhuànzhěménzhěnzhìliáozhēnshíshìjièyánjiū |